8-K: Sonnet BioTherapeutics Announces $888 Million Business Combination to Pivot to Cryptocurrency Treasury Strategy

Sonnet BioTherapeutics Holdings, Inc. has entered into a definitive agreement for a business combination with Rorschach I LLC, forming Hyperliquid Strategies Inc. (HSI), which will pivot to a cryptocurrency treasury strategy focused on HYPE tokens, valued at an estimated $888 million at closing.

Summary

• Sonnet BioTherapeutics Holdings, Inc. (SONN) is undergoing a business combination with Rorschach I LLC, a newly formed entity affiliated with Atlas Merchant Capital LLC and Paradigm Operations LP, to create Hyperliquid Strategies Inc. (HSI).
• HSI is expected to hold approximately 12.6 million HYPE tokens, valued at $583 million (based on a spot price of $46.372 per HYPE token), and will have gross cash of at least $305 million on its balance sheet at closing, totaling an assumed closing value of $888 million.
• The transaction includes participation from prominent strategic investors such as Paradigm, Galaxy Digital, Pantera Capital, D1 Capital, Republic Digital, and 683 Capital.
• Current Sonnet equityholders (including initial PIPE investors) are expected to own approximately 1.2% of HSI's outstanding common stock post-closing, while Rorschach equityholders and new subscribers will own approximately 98.8%.
• Sonnet will raise an aggregate of $5.5 million in a private placement through the issuance of Series 5 Convertible Preferred Stock and warrants, with an additional $2.0 million in convertible notes from June 2025 converting into the same securities.
• Sonnet common shareholders and certain other equity holders will receive a Contingent Value Right (CVR) for each share of common stock held, representing a right to receive Pubco Common Stock from 85% of Net Proceeds from the sale or monetization of Sonnet's existing biotech assets (Company Legacy Assets) over a three-year term.
• The CVRs are non-transferable (with limited exceptions) and will not be listed on any exchange, and there is no assurance that CVR holders will receive any payments.
• The closing of the business combination is anticipated in the second half of 2025, subject to Sonnet stockholder approval and other customary closing conditions.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the significant capital infusion and strategic pivot into a high-growth, albeit volatile, sector with strong institutional backing. However, this is tempered by substantial dilution for existing shareholders, high regulatory and market risks associated with cryptocurrency, and the speculative nature of the CVRs for legacy assets.

Positives

• The transaction provides Sonnet with a significant capital infusion, with HSI expected to hold at least $305 million in cash, enabling further HYPE acquisition and supporting Sonnet's existing biotech assets.
• The strategic pivot to a cryptocurrency treasury strategy, particularly focusing on HYPE, positions the combined entity in a rapidly evolving and potentially high-growth digital asset sector.
• The involvement of prominent investors like Paradigm, Galaxy Digital, and Pantera Capital lends credibility and significant backing to the new HSI entity and its digital asset strategy.
• The appointment of experienced financial and crypto industry leaders, including Bob Diamond as Chairman and David Schamis as CEO of HSI, brings strong leadership to the new venture.
• The Contingent Value Rights (CVRs) offer existing Sonnet shareholders a potential future upside from the monetization of the company's legacy biotech assets, allowing them to participate in both the new crypto strategy and the existing pipeline.

Negatives

• Existing Sonnet equityholders will experience significant dilution, owning only approximately 1.2% of the combined entity (HSI) post-closing.
• The new business strategy is highly exposed to the extreme volatility of HYPE tokens and the broader cryptocurrency market, which can significantly impact financial results and stock price.
• The digital asset industry faces substantial legal and regulatory uncertainty, including the risk of HYPE being classified as a security, which could subject HSI to stringent and potentially impractical regulations under the Investment Company Act of 1940.
• The CVRs are non-transferable and highly speculative, with no guarantee of any payment, and are subject to significant deductions and the successful monetization of legacy biotech assets within a three-year term.
• The concentration of HSI's treasury in HYPE tokens limits diversification and enhances the financial impact of any significant decline in HYPE's price.
• The company acknowledges that its historical financial statements do not reflect the potential variability in earnings due to HYPE holdings, and new accounting standards (ASU 2023-08) will introduce fair value accounting, increasing earnings volatility.

Risks

• Completion of the Mergers is subject to conditions, including stockholder approval and absence of legal restraints, which may not be satisfied or completed on a timely basis or at all, leading to significant costs and disruption.
• HYPE is a highly volatile asset, and fluctuations in its price may adversely influence financial results and the market price of listed securities.
• The price of HYPE could decrease due to factors such as decreased user confidence, significant dispositions by large holders, negative publicity, competition from other blockchains, or macroeconomic changes.
• HYPE and other digital assets are subject to significant legal and regulatory uncertainty, with potential for new laws, regulations, or enforcement actions that could adversely affect Hyperliquid's operations, HYPE's price, or the ability to own/transfer HYPE.
• The HYPE treasury strategy subjects HSI to enhanced regulatory oversight, including anti-money laundering and sanctions laws, potentially leading to restrictions or prohibitions on HYPE transactions.
• There is a risk that HYPE may be classified as a security, which could require HSI to register as an investment company under the Investment Company Act of 1940, making its business impractical and leading to significant penalties.
• Disruptions to the peer-to-peer Hyperliquid network, such as price volatility, insolvency of participants/custodians, security breaches, or network congestion, could negatively impact HYPE's value.
• Risks related to the custody of HYPE include loss or destruction of private keys, cyberattacks, smart contract vulnerabilities, limited insurance coverage, and the possibility of being treated as an unsecured creditor in custodian insolvency proceedings.
• Unrealized fair value gains on HYPE holdings could subject HSI to the 15% corporate alternative minimum tax (CAMT) under the Inflation Reduction Act of 2022, requiring significant cash tax obligations.
• The unregulated nature and lack of transparency of many HYPE trading venues may lead to greater fraud, security failures, or operational problems, adversely affecting HYPE's value and investor confidence.
• The concentration of HSI's HYPE holdings limits risk mitigation compared to a diversified portfolio, making it more vulnerable to HYPE price declines.
• The emergence or growth of other blockchains and digital assets could negatively impact HYPE's price and HSI's business.
• HYPE holdings are less liquid than cash and cash equivalents, potentially limiting HSI's ability to meet working capital requirements or generate funds during market instability.

Future Outlook

The combined entity, Hyperliquid Strategies Inc. (HSI), will focus on building a reserve of HYPE tokens and operating a cryptocurrency treasury strategy. Sonnet BioTherapeutics, as a wholly-owned subsidiary of HSI, will continue to focus on its existing biotech assets, including SON-1010, and engage in commercial partnering discussions for their disposition. HSI is expected to remain listed on Nasdaq under a new ticker symbol. The gross cash proceeds from the business combination are intended to enable HSI to acquire significantly more HYPE tokens. The company anticipates potential yield generation from deploying HYPE into HyperEVM for various DeFi strategies, which can be compounded into its overall HYPE acquisition strategy.

Management Comments

• Bob Diamond, Co-founder and CEO of Atlas, commented: "We are delighted by this opportunity to partner with Sonnet in establishing a leading crypto treasury management strategy to ultimately deliver strong value to shareholders. We believe HYPE and the Hyperliquid protocol represent a truly differentiated offering within the digital asset space. We believe Hyperliquid Strategies will be well placed to maximize these opportunities because of our unique team of investors and operators with deep, relevant crypto and financial services experience."
• Matt Huang, Co-founder of Paradigm, added: "Hyperliquid has broken out as a crypto project with real fundamentals: strong core contributors, exacting product quality, and meteoric growth. We hear lots of institutional demand for exposure to Hyperliquid, yet the native token HYPE is difficult to access in the United States. We are excited about this treasury strategy, which we believe will contribute to the Hyperliquid ecosystem in many ways over time."
• Raghu Rao, Sonnet's Interim Chief Executive Officer, commented: "Following a thorough review, we believe this proposed combination with Rorschach provides us with a unique and exciting opportunity. We will be able to capitalize on the recent advancements around digital assets and equip Sonnet with funding to potentially realize the future value of our existing biotech assets. We believe this transaction and the strategic options it provides offer Sonnet and our shareholders with an innovative path forward and the potential for significant value creation."
• Nailesh Bhatt, Chairman of the Board of Directors of Sonnet, added: "On behalf of the Sonnet Board, we are incredibly grateful to Raghu for stepping in as interim CEO and spearheading the operational and strategic efforts despite the turbulent times. We believe this transaction holds a lot of promise and opportunity, and we are dedicatedly working to bring it to fruition. Raghu along with the rest of the leadership at Sonnet attributed significant efforts into determining the best path forward and we believe this transaction clearly represents just that. We are excited for the next phase ahead and look forward to optimizing value for all stakeholders."

Industry Context

This announcement signifies a significant strategic pivot for Sonnet BioTherapeutics, moving from a pure-play oncology-focused biotechnology company to a 'cryptocurrency treasury company' focused on the HYPE token. This move reflects a broader trend of companies exploring digital assets for treasury management and strategic growth, particularly as the cryptocurrency market matures and institutional interest grows. The focus on HYPE, a native token of a Layer-1 blockchain designed for high-frequency decentralized transactions and smart contracts, positions HSI within the DeFi (Decentralized Finance) and blockchain infrastructure sectors. The involvement of major crypto investment firms like Paradigm and Galaxy Digital suggests a belief in the long-term potential of the Hyperliquid ecosystem and the HYPE token, despite the inherent volatility and regulatory uncertainties of the crypto industry.

Comparison to Industry Standards

• The document does not provide specific comparable companies, projects, or results for direct comparison to industry standards in either the biotechnology or cryptocurrency sectors. The focus is on the strategic shift and the potential of the HYPE token within its specific ecosystem (Hyperliquid Layer-1 blockchain).
• While HYPE is noted as the '13th-largest cryptocurrency by market capitalization per Forbes as of July 6th, 2025,' this is a market ranking, not a direct comparison of performance or operational metrics against industry benchmarks.
• The document highlights Hyperliquid's technical capabilities, such as 'fully on-chain perpetual futures and spot order books with ~200K orders / second currently being supported,' which implies a focus on high-performance decentralized exchange infrastructure. However, no specific performance benchmarks against competitors in this niche are provided.
• The strategy of holding a significant reserve of a native token and potentially earning yield through DeFi applications is a common, albeit risky, strategy among crypto-focused entities, but no specific comparable yield or return metrics are presented.

Management Changes

Corporate Governance

Legal Proceedings

• The document mentions that the SEC announced the formation of a Crypto Task Force in January 2025 to provide clarity on federal securities laws' application to crypto assets.
• It notes that in April and August 2024, Uniswap Labs and OpenSea, respectively, publicized receiving Wells Notices from the SEC regarding allegations of operating as unregistered securities exchanges.
• In November 2023, Binance Holdings Ltd. and its CEO settled with the U.S. Department of Justice, CFTC, OFAC, and FinCEN for $4.3 billion in penalties, and the SEC filed a complaint against Payward Inc. and Payward Ventures Inc. (Kraken) for allegedly operating as unregistered securities exchanges, brokers, dealers, and clearing agencies.
• In June 2023, the SEC filed complaints against Binance and Coinbase, Inc. for similar allegations.
• While the complaints against Coinbase, Payward Inc., Payward Ventures Inc., and Binance were dismissed in February, March, and May 2025 respectively, the document highlights that the SEC or other regulatory agencies may initiate similar actions in the future, citing a civil enforcement action by the State of Oregon against Coinbase in April 2025 for allegedly selling unregistered securities.
• No new specific legal proceedings are disclosed as pending or threatened directly against Sonnet BioTherapeutics or the Rorschach entities in connection with their existing operations, but the risks section extensively details the potential for such proceedings due to the new cryptocurrency treasury strategy and the evolving regulatory landscape for digital assets.

Related Party Transactions

• The Business Combination Agreement is between Sonnet BioTherapeutics Holdings, Inc. and Rorschach I LLC, a newly-formed entity formed by an entity affiliated with Atlas Merchant Capital LLC and Paradigm Operations LP, and additional sponsors. This constitutes a significant related-party transaction as it involves a fundamental change in the company's business and ownership structure driven by these affiliated entities.
• The Subscription Agreements for the Closing PIPE are with 'certain accredited investors' (Subscribers) who, collectively with Rorschach equityholders, will own approximately 98.8% of Pubco Common Stock post-closing, indicating these are likely related parties or strategic investors closely aligned with the Rorschach/Atlas/Paradigm group.
• The Contribution Agreements involve 'certain investors' contributing HYPE Tokens and/or cash to Rorschach, which are then transferred to Pubco, further indicating related party involvement in funding the new entity's treasury.
• The Advisor Rights Agreement and Strategic Advisor Agreement are between Pubco and Rorschach Advisors LLC (the Advisor), which is the entity receiving significant equity and warrants in Pubco and providing advisory services, clearly defining a related-party relationship for ongoing governance and strategic input.
• The RSU grants to Donald Griffith (CFO), John Cini (CSO), and Raghu Rao (Interim CEO) are compensatory arrangements with key management personnel, which are standard but are related-party transactions.

Stakeholder Impact

• **Shareholders (Existing Sonnet Common Stockholders):** Will experience significant dilution, owning only ~1.2% of the combined entity (HSI). They will receive Contingent Value Rights (CVRs) which offer a speculative, non-transferable, and unlisted right to potential future proceeds from Sonnet's legacy biotech assets, subject to deductions and no guarantee of payment. This represents a substantial shift in their investment thesis from biotech to a crypto-focused company.
• **New Investors (Rorschach Equityholders & Subscribers):** Will collectively own ~98.8% of HSI, gaining significant control and exposure to the new cryptocurrency treasury strategy. Their investment is central to the combined entity's capital base and strategic direction.
• **Employees (Sonnet):** The company states that Sonnet will operate as a wholly-owned subsidiary of HSI and will continue focusing on existing assets, with Raghu Rao remaining CEO of the subsidiary. This suggests continuity for some employees, particularly those involved in biotech development. However, the strategic shift may lead to changes in focus or personnel over time.
• **Management (Sonnet & HSI):** Key Sonnet officers (Raghu Rao, Donald Griffith, John Cini) received RSU grants, indicating their continued involvement. New leadership for HSI (Robert Diamond as Chairman, David Schamis as CEO) will drive the new crypto strategy, impacting the overall corporate culture and strategic direction.
• **Customers/Partners (Sonnet's Biotech Business):** Sonnet will continue to engage in commercial partnering discussions focused on its biotech assets. The CVR mechanism is designed to monetize these assets, implying that existing or potential partners for biotech programs will interact with Sonnet as a subsidiary focused on these legacy assets.
• **Regulatory Authorities:** The strategic pivot to a cryptocurrency treasury company will likely increase scrutiny from regulatory bodies like the SEC, particularly concerning the classification of HYPE as a security and compliance with evolving digital asset regulations. The company explicitly highlights enhanced regulatory oversight as a risk.

Next Steps

• Sonnet will seek approval from its stockholders for the Business Combination Agreement and related transactions.
• Pubco will prepare and file a registration statement on Form S-4 to register the shares of Pubco Common Stock to be issued in connection with the Mergers.
• The parties will work to cause the Registration Statement to be declared effective by the SEC.
• Sonnet will mail a definitive proxy statement/prospectus to its stockholders.
• The parties will work to obtain listing approval for Pubco Common Stock on Nasdaq.
• The closing of the Business Combination is expected to occur in the second half of 2025.
• Sonnet, as a wholly-owned subsidiary of HSI, will continue focusing on existing biotech assets and business lines, including the development of SON-1010, while disposing of other assets.
• Sonnet will continue to engage in commercial partnering discussions focused on its biotech assets for potential monetization via Company Legacy Transactions.

Key Dates

Keywords

Hyperliquid Strategies Inc, HYPE token, Cryptocurrency treasury, Business combination, Sonnet BioTherapeutics, Rorschach I LLC, Digital assets, Blockchain, SEC filing, Merger, Contingent Value Rights, PIPE offering, Corporate governance, Risk management, Biotechnology assets